Investors are hoping that orforglipron will be a major growth catalyst for Lilly
Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs
On August 1, 2025, the JPML reported there are 2,190 cases pending in MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
Shamsah Amersi, an OB-GYN who specializes in womens health and metabolic medicine, describes it this way: The body responds to consistency, not intensity. In her practice, she starts patients at 0.05 to 0.1 mg of semaglutide weekly and watches for three things: Appetite changes : Most patients notice subtle but real shifts within two to four weeks
Self-paying customers historically had to fork out nearly $1000 per month for injectable GLP-1 drugs, although Novo Nordisk slashed this price at the end of last year
Treatment of human pancreas cancer cell line (Panc-1) cells with 8-OhdG resulted in decreased total cellular ROS production and a reduction of Nox1, Nox2 and Nox3 mRNA expression
